PLASMA-LYTE A IN PLASTIC CONTAINER

Clinical safety rating: caution

Comprehensive clinical and safety monograph for PLASMA-LYTE A IN PLASTIC CONTAINER (PLASMA-LYTE A IN PLASTIC CONTAINER).

How it works

Maintenance and restoration of fluid and electrolyte balance; provides isotonic crystalloid solution with sodium, potassium, magnesium, chloride, and acetate/bicarbonate precursors to buffer acidity.

What the body does with it

Metabolism	Acetate and gluconate are metabolized to bicarbonate primarily in the liver and kidneys; electrolytes are excreted unchanged via kidneys.
Excretion	Electrolytes and water are primarily excreted renally: sodium (90-95% filtered, reabsorbed), chloride (follows sodium), potassium (80-90% renal, 10% fecal), magnesium (30-50% reabsorbed, remainder excreted), acetate (metabolized to bicarbonate, ultimately renal). Fluid volume is regulated by renal mechanisms (ADH, aldosterone). Essentially 100% of administered volume and electrolytes are eliminated via kidneys under normal physiology.
Half-life	Not applicable as a single half-life; electrolytes have distribution and elimination phases governed by body stores and renal function. For water, elimination half-life is ~2-4 hours in euvolemic individuals with normal GFR. Clinically, infused volume distributes within ~30 minutes and is renally cleared over several hours.
Protein binding	None significant; electrolytes are free in plasma (sodium, chloride, potassium, magnesium are not protein-bound). Acetate is rapidly metabolized.
Volume of Distribution	Electrolytes: 0.2 L/kg for sodium and chloride (extracellular fluid); water: total body water ~0.6 L/kg. Clinical meaning: Vd of electrolytes approximates ECF volume; water distributes throughout total body water.
Bioavailability	Not applicable for IV route; bioavailability is 100% by definition.
Onset of Action	IV: Immediate (within seconds to minutes) for volume expansion and electrolyte effect, as infusion directly enters bloodstream.
Duration of Action	Volume effect lasts 1-2 hours in euvolemic patients; electrolyte effects persist until renal excretion. In hypovolemia, duration may be shorter due to rapid distribution.

Classification & Brands

Dosing & administration

Intravenous infusion; adult dose is based on electrolyte and fluid requirements, typically 500-1000 mL/hour initially, then adjusted; maximum rate 30 mL/kg/hour.

Dosage form	INJECTABLE
Renal impairment	No specific GFR-based dose adjustment; contraindicated in severe renal impairment with oliguria or anuria.
Liver impairment	No specific Child-Pugh based adjustment; use with caution in severe hepatic impairment due to risk of electrolyte imbalances.
Pediatric use	Intravenous infusion; dose based on weight: 5-20 mL/kg/hour initially, adjusted according to clinical response and laboratory values; maximum 50 mL/kg/day.
Geriatric use	Use with caution due to increased risk of fluid overload and electrolyte disturbances; monitor renal function and adjust rate accordingly.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for PLASMA-LYTE A IN PLASTIC CONTAINER (PLASMA-LYTE A IN PLASTIC CONTAINER).

Breastfeeding	Excretion into human milk unknown; M/P ratio not applicable. Use with caution.
Teratogenic Risk	No known teratogenic effects in any trimester.
Fetal Monitoring	Monitor serum electrolytes, fluid balance, and renal function.

Warnings & precautions

■ FDA Black Box Warning

None

Side Effect Profile

Serious Effects

Absolute Contraindications

["Hypersensitivity to any component","Severe hyperkalemia","Severe hypernatremia","Severe metabolic alkalosis","Patients with anuria or severe renal failure (relative)"]

Clinical Precautions

Precautions

["Use with caution in patients with congestive heart failure, severe renal impairment, or conditions predisposing to fluid overload","Monitor serum electrolytes and acid-base balance regularly","Contains aluminum, which may be toxic with prolonged use in renal impairment","Risk of hyperkalemia in patients with renal failure or potassium-retaining medications"]

Clinical Tips & Counseling

Drug interactions

Loading safety data…

PLASMA-LYTE A IN PLASTIC CONTAINER

Clinical safety rating: caution

Comprehensive clinical and safety monograph for PLASMA-LYTE A IN PLASTIC CONTAINER (PLASMA-LYTE A IN PLASTIC CONTAINER).

How it works

Maintenance and restoration of fluid and electrolyte balance; provides isotonic crystalloid solution with sodium, potassium, magnesium, chloride, and acetate/bicarbonate precursors to buffer acidity.

What the body does with it

Metabolism	Acetate and gluconate are metabolized to bicarbonate primarily in the liver and kidneys; electrolytes are excreted unchanged via kidneys.
Excretion	Electrolytes and water are primarily excreted renally: sodium (90-95% filtered, reabsorbed), chloride (follows sodium), potassium (80-90% renal, 10% fecal), magnesium (30-50% reabsorbed, remainder excreted), acetate (metabolized to bicarbonate, ultimately renal). Fluid volume is regulated by renal mechanisms (ADH, aldosterone). Essentially 100% of administered volume and electrolytes are eliminated via kidneys under normal physiology.
Half-life	Not applicable as a single half-life; electrolytes have distribution and elimination phases governed by body stores and renal function. For water, elimination half-life is ~2-4 hours in euvolemic individuals with normal GFR. Clinically, infused volume distributes within ~30 minutes and is renally cleared over several hours.
Protein binding	None significant; electrolytes are free in plasma (sodium, chloride, potassium, magnesium are not protein-bound). Acetate is rapidly metabolized.
Volume of Distribution	Electrolytes: 0.2 L/kg for sodium and chloride (extracellular fluid); water: total body water ~0.6 L/kg. Clinical meaning: Vd of electrolytes approximates ECF volume; water distributes throughout total body water.
Bioavailability	Not applicable for IV route; bioavailability is 100% by definition.
Onset of Action	IV: Immediate (within seconds to minutes) for volume expansion and electrolyte effect, as infusion directly enters bloodstream.
Duration of Action	Volume effect lasts 1-2 hours in euvolemic patients; electrolyte effects persist until renal excretion. In hypovolemia, duration may be shorter due to rapid distribution.

Classification & Brands

Dosing & administration

Intravenous infusion; adult dose is based on electrolyte and fluid requirements, typically 500-1000 mL/hour initially, then adjusted; maximum rate 30 mL/kg/hour.

Dosage form	INJECTABLE
Renal impairment	No specific GFR-based dose adjustment; contraindicated in severe renal impairment with oliguria or anuria.
Liver impairment	No specific Child-Pugh based adjustment; use with caution in severe hepatic impairment due to risk of electrolyte imbalances.
Pediatric use	Intravenous infusion; dose based on weight: 5-20 mL/kg/hour initially, adjusted according to clinical response and laboratory values; maximum 50 mL/kg/day.
Geriatric use	Use with caution due to increased risk of fluid overload and electrolyte disturbances; monitor renal function and adjust rate accordingly.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for PLASMA-LYTE A IN PLASTIC CONTAINER (PLASMA-LYTE A IN PLASTIC CONTAINER).

Breastfeeding	Excretion into human milk unknown; M/P ratio not applicable. Use with caution.
Teratogenic Risk	No known teratogenic effects in any trimester.
Fetal Monitoring	Monitor serum electrolytes, fluid balance, and renal function.

Warnings & precautions

■ FDA Black Box Warning

None

Side Effect Profile

Serious Effects

Absolute Contraindications

["Hypersensitivity to any component","Severe hyperkalemia","Severe hypernatremia","Severe metabolic alkalosis","Patients with anuria or severe renal failure (relative)"]